Clinical commentary on evidence, oncology decisions, clinical knowledge, and where technology belongs.https://kesis.ca/en-CAhttps://kesis.ca/insights/when-i-look-at-medical-ai-i-start-with-the-patients/https://kesis.ca/insights/when-i-look-at-medical-ai-i-start-with-the-patients/I approach medical AI with the same questions I bring to a clinical trial: who was studied, how dependable is the answer, and will it help the person in front of me?Tue, 22 Sep 2026 00:00:00 GMTClinical CommentaryDr. Henry Conterhttps://kesis.ca/insights/i-gave-codex-a-chalk-talk/https://kesis.ca/insights/i-gave-codex-a-chalk-talk/On a walk, I taught Codex how to make a presentation and learned from the exchange. A study of developers asks what stays with us after AI helps finish the work.Mon, 14 Sep 2026 00:00:00 GMTIndustry & StrategyDr. Henry Conterhttps://kesis.ca/insights/how-much-benefit-would-make-this-worth-it/https://kesis.ca/insights/how-much-benefit-would-make-this-worth-it/At a case conference, chemotherapy seemed obvious to many colleagues. I thought the patient had a meaningful choice. What was inside that disagreement?Mon, 07 Sep 2026 00:00:00 GMTClinical CommentaryDr. Henry Conterhttps://kesis.ca/insights/ten-billion-tokens-later/https://kesis.ca/insights/ten-billion-tokens-later/I switched to OpenAI on July 13 and reached 10.1 billion tokens 48 days later. The work behind that number changed how I lead agents and build medical knowledge.Wed, 02 Sep 2026 00:00:00 GMTIndustry & StrategyDr. Henry Conterhttps://kesis.ca/insights/where-is-the-clinician-baseline-table/https://kesis.ca/insights/where-is-the-clinician-baseline-table/A dermatology study measured decisions before and after advice from artificial intelligence. It raises a question that job titles do not answer: what can the intended user do without the system?Mon, 31 Aug 2026 00:00:00 GMTDecision SupportDr. Henry Conterhttps://kesis.ca/insights/canadas-trade-conflict-should-make-us-rethink-what-it-means-to-own-technology/https://kesis.ca/insights/canadas-trade-conflict-should-make-us-rethink-what-it-means-to-own-technology/A Canadian can pay full price for a machine and still be blocked from making it better. That belongs in Canada’s trade fight.Sun, 23 Aug 2026 00:00:00 GMTIndustry & StrategyDr. Henry Conterhttps://kesis.ca/insights/the-machine-got-the-right-answer-without-doing-all-the-work/https://kesis.ca/insights/the-machine-got-the-right-answer-without-doing-all-the-work/A Nyx run reached the clinical conclusion we kept and still failed. Missing support links show why a sound answer may still be unfinished work.Wed, 19 Aug 2026 00:00:00 GMTIndustry & StrategyDr. Henry Conterhttps://kesis.ca/insights/the-endpoint-we-had-already-chosen/https://kesis.ca/insights/the-endpoint-we-had-already-chosen/PFS formalizes how patients, clinicians, and HTA models understand cancer control, even though it does not reliably predict overall survival. Its clinical meaning holds only when the trial endpoint obeys the same model.Mon, 17 Aug 2026 00:00:00 GMTClinical CommentaryDr. Henry Conterhttps://kesis.ca/insights/overall-survival-is-the-weaker-endpoint/https://kesis.ca/insights/overall-survival-is-the-weaker-endpoint/Overall survival measures an entire treatment pathway. PFS may be the stronger endpoint for the treatment decision a trial was designed to test.Mon, 10 Aug 2026 00:00:00 GMTClinical CommentaryDr. Henry Conterhttps://kesis.ca/insights/the-manager-was-set-to-medium/https://kesis.ca/insights/the-manager-was-set-to-medium/The specialists needed XHigh reasoning. Their orchestrators ran best at Medium. Another workflow used 13.5 million tokens on alignment alone.Thu, 06 Aug 2026 00:00:00 GMTIndustry & StrategyDr. Henry Conterhttps://kesis.ca/insights/the-human-in-the-loop-is-a-regulatory-fiction/https://kesis.ca/insights/the-human-in-the-loop-is-a-regulatory-fiction/In oncology, a clinician cannot inspect, verify, or control a generative model. Physician review cannot become a liability shield for the companies that put it into clinical use.Tue, 04 Aug 2026 00:00:00 GMTIndustry & StrategyDr. Henry Conterhttps://kesis.ca/insights/the-claim-stops-where-the-evidence-stops/https://kesis.ca/insights/the-claim-stops-where-the-evidence-stops/A 9,691-patient trial shows why better documentation, better decisions, and better outcomes require separate evidence.Mon, 27 Jul 2026 00:00:00 GMTDecision SupportDr. Henry Conterhttps://kesis.ca/insights/i-found-out-about-build-week-on-friday-night/https://kesis.ca/insights/i-found-out-about-build-week-on-friday-night/I found OpenAI Build Week on Friday night, built Ariad by Tuesday, and learned why fast clinical products still need reliable medical knowledge.Wed, 22 Jul 2026 00:00:00 GMTIndustry & StrategyDr. Henry Conterhttps://kesis.ca/insights/the-treatment-he-could-not-get-still-belonged-in-the-conversation/https://kesis.ca/insights/the-treatment-he-could-not-get-still-belonged-in-the-conversation/An Ontario oncologist discussed a treatment the system could not yet provide. That conversation matters for patients, clinical records, and funding decisions.Tue, 14 Jul 2026 00:00:00 GMTClinical CommentaryDr. Henry Conterhttps://kesis.ca/insights/the-hardest-decision-in-oncology-is-the-one-you-never-get-to-check/https://kesis.ca/insights/the-hardest-decision-in-oncology-is-the-one-you-never-get-to-check/Why the survival benefit number from an adjuvant trial is never the number a patient is asking for — and where decision support can close that gap.Tue, 16 Jun 2026 00:00:00 GMTClinical CommentaryDr. Henry Conterhttps://kesis.ca/insights/canada-is-building-the-foundation-the-value-is-one-layer-up/https://kesis.ca/insights/canada-is-building-the-foundation-the-value-is-one-layer-up/Canada is building sovereign AI infrastructure for health. The durable value will be made in the layer that turns it into better decisions at the bedside.Tue, 09 Jun 2026 00:00:00 GMTIndustry & StrategyDr. Henry Conterhttps://kesis.ca/insights/the-doctors-who-use-ai-were-never-worried-about-it/https://kesis.ca/insights/the-doctors-who-use-ai-were-never-worried-about-it/AI researchers are walking back doomsday predictions. In oncology the reversal is unsurprising — these tools help with what clinicians never had time to finish.Tue, 02 Jun 2026 00:00:00 GMTIndustry & StrategyDr. Henry Conterhttps://kesis.ca/insights/we-turn-your-survival-curves-into-yes-or-no/https://kesis.ca/insights/we-turn-your-survival-curves-into-yes-or-no/Pharma invests years in continuous trial data. By the time it reaches clinic, most of that precision is gone. Here's where the value actually goes.Tue, 26 May 2026 00:00:00 GMTClinical CommentaryDr. Henry Conterhttps://kesis.ca/insights/what-oncologists-actually-want-from-clinical-decision-support/https://kesis.ca/insights/what-oncologists-actually-want-from-clinical-decision-support/Most CDS tools assume doctors need help remembering guidelines. That's not where oncologists get stuck. Here's what the harder conversations actually look like.Thu, 21 May 2026 00:00:00 GMTDecision SupportDr. Henry Conter